These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1742 related articles for article (PubMed ID: 31780379)

  • 1. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
    Sammons S; Shastry M; Dent S; Anders C; Hamilton E
    Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
    Mayer EL; Ren Y; Wagle N; Mahtani R; Ma C; DeMichele A; Cristofanilli M; Meisel J; Miller KD; Abdou Y; Riley EC; Qamar R; Sharma P; Reid S; Sinclair N; Faggen M; Block CC; Ko N; Partridge AH; Chen WY; DeMeo M; Attaya V; Okpoebo A; Alberti J; Liu Y; Gauthier E; Burstein HJ; Regan MM; Tolaney SM
    J Clin Oncol; 2024 Jun; 42(17):2050-2060. PubMed ID: 38513188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
    Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
    Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparities in receipt of 1-
    Pilehvari A; Kimmick G; You W; Bonilla G; Anderson R
    Breast Cancer Res; 2024 Oct; 26(1):144. PubMed ID: 39425174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
    Schwartzberg LS; Vidal GA
    Clin Breast Cancer; 2020 Aug; 20(4):e439-e449. PubMed ID: 32278641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
    Schettini F; Palleschi M; Mannozzi F; Brasó-Maristany F; Cecconetto L; Galván P; Mariotti M; Ferrari A; Scarpi E; Miserocchi A; Nanni O; Sanfeliu E; Prat A; Rocca A; De Giorgi U
    Oncologist; 2024 May; 29(5):e622-e634. PubMed ID: 38175669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
    Del Re M; Crucitta S; Lorenzini G; De Angelis C; Diodati L; Cavallero D; Bargagna I; Cinacchi P; Fratini B; Salvadori B; Ghilli M; Roncella M; Fontana A; Danesi R; Cucchiara F
    Pharmacol Res; 2021 Jan; 163():105241. PubMed ID: 33049397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
    Sánchez-Bayona R; Lopez de Sa A; Jerez Gilarranz Y; Sanchez de Torre A; Alva M; Echavarria I; Moreno F; Tolosa P; Herrero Lopez B; de Luna A; Lema L; Gamez Casado S; Madariaga A; López-Tarruella S; Manso L; Bueno-Muiño C; Garcia-Saenz JA; Ciruelos E; Martin M
    Breast Cancer Res Treat; 2024 Aug; 206(3):551-559. PubMed ID: 38703285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
    Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
    BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
    Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
    Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
    Bardia A; Cortés J; Bidard FC; Neven P; Garcia-Sáenz J; Aftimos P; O'Shaughnessy J; Lu J; Tonini G; Scartoni S; Paoli A; Binaschi M; Wasserman T; Kaklamani V
    Clin Cancer Res; 2024 Oct; 30(19):4299-4309. PubMed ID: 39087959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
    Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J; Ma CX
    Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of SERENA-6, a phase III switching trial of camizestrant in
    Turner N; Huang-Bartlett C; Kalinsky K; Cristofanilli M; Bianchini G; Chia S; Iwata H; Janni W; Ma CX; Mayer EL; Park YH; Fox S; Liu X; McClain S; Bidard FC
    Future Oncol; 2023 Mar; 19(8):559-573. PubMed ID: 37070653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
    Brett JO; Spring LM; Bardia A; Wander SA
    Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.